QR kód

Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260)

The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-res...

Celý popis

Uloženo v:
Vydáno v:Antimicrob Agents Chemother
Hlavní autoři: Demeter, L. M., Shafer, R. W., Meehan, P. M., Holden-Wiltse, J., Fischl, M. A., Freimuth, W. W., Para, M. F., Reichman, R. C.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology (ASM) 2000
Témata:
Antiviral Agents
On-line přístup:https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC89771/
https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10681363/
https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.44.3.794-797.2000
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky